California Life Sciences Association (CLSA) welcomes the introduction of H.R. 4617, legislation that places a 5-year freeze on the ill-conceived 2.3% medical device excise tax. Without swift enactment of this measure, the medical device tax would further hamper innovation and investment in medical technology research and development.
California Life Sciences Association (CLSA) and PwC US newly released annual California Life Sciences Industry Report, provides a snapshot of the largest life sciences cluster in the world. The 2018 report shows that California continues to outpace other states in life science-related economic growth, including venture funding, National Institutes of Health (NIH) funding, digital health venture funding, and is producing nearly 300,000 jobs and shepherding more than a thousand new therapies through the pipeline.
For over 7 years, CLSA has advocacted for repeal of IPAB because such blunt cost containment approaches could seriously harm the delicate cycle of biomedical innovation by reducing incentives for investment in new research and product development, and ultimately limit patient access to lifesaving treatments, therapies and technologies.
Esteemed Industry Leaders to be Honored for Contributions to California’s Thriving Life Sciences Sector on Nov. 10
California Life Sciences Association (CLSA), the statewide public policy and business leadership trade association representing California’s life sciences industry, today announced winners of the 2017 Pantheon DiNA Awards, a distinguished awards program honoring innovation and excellence within California’s life sciences sector.
Six Board Appointments Add Leadership from Bay City Capital, BD, Cal State Long Beach, Celgene, Genentech and USC
U.S. Senate Approves Measure to Support Operations at the FDA to Help Propel Bioscience & MedTech Investment and Innovation
Sponsored by CLSA, AB 602 Protects Patients with Diabetes from Counterfeit or Improperly Sold Diabetes Test Devices
California Life Sciences Association (CLSA) applauds Governor Jerry Brown, California State Senate and California Assembly leaders for their strong support of life sciences innovation, as demonstrated again in this year’s 2017-2018 budget deal which allocates a $10 million investment in precision medicine research.
California Life Sciences Association (CLSA), the premier public policy advocacy and business leadership trade association representing California’s life sciences industry, today issued the following statement in response to the President’s FY 2018 budget request.